Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
about
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsA model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study designPharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patientsPopulation pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy VolunteersPopulation pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab.Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.A guide to rational dosing of monoclonal antibodies.The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.Clinical pharmacology considerations in biologics development.Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?Challenges and considerations for development of therapeutic proteins in pediatric patients.Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Fixed Dosing of Monoclonal Antibodies in Oncology.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.Evaluation of dosing strategy for pembrolizumab for oncology indications.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Drug Development of Therapeutic Monoclonal Antibodies.Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients.Effect of correlation on covariate selection in linear and nonlinear mixed effect models.Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study.Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug dispositionPopulation pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.
P2860
Q26849243-52CC928C-EFD8-4765-A86A-39FF2152A283Q34223916-B09B7AFA-53C3-4C6B-887F-4E741D61622CQ35183631-F2D3D521-EE78-4B68-AE1A-488DB5B40F6CQ35692016-D806E481-BB02-4B05-8B8B-C30DEECB38E0Q36243612-18525528-3744-4C43-9925-FAA073874DF0Q36706795-4E581854-B06C-470B-90D5-291BECD03D52Q36806646-693917D0-3361-42C5-8AE2-9B56F2098312Q37030693-0D6E18AC-0B84-466A-8AE4-EAD236F1FBD8Q37182157-26FC16DC-756A-4730-8C00-A9A628DF143EQ37203832-A0FDF4F8-F83F-436F-96B9-D0FEC724E548Q37298794-BBC919A4-B0D1-4689-B095-F837B9D27875Q37541753-D49E418C-7C1F-4874-BA8A-635D1B146AA4Q37609771-A69E14E8-E286-4395-8BA1-FA035E24CE71Q37976878-CC446D8C-2203-4741-997E-7E1B0E0B8E56Q37996075-D7102010-5D59-400C-90FE-3B774034756FQ38045792-72331EA8-C574-4984-936B-18576C14E357Q38074900-1D299D71-3059-4ADA-A3C7-5843D0954D68Q38163447-6AAA5007-586A-477E-BD68-0A795706984CQ38364457-E7A7BDD3-89EC-45FF-8381-E8F366A67737Q38375170-A87ECA90-B48C-426F-B77E-7385B52585A7Q38564877-E8D78F64-61D6-4D4D-BA4D-9D8108767585Q38654371-8C535C74-5265-4702-B8E7-70D386A66980Q38714339-1F738053-7180-44B3-8EEA-E964A40DF0CEQ38736222-72535F5F-2266-4BA3-A342-4BB2BC617790Q38779793-0E29F37E-4DE7-4DA0-9BA2-D865C9A7739EQ38831148-9C6E28C3-BC36-44C5-B8FB-C61A3E2427C5Q38876360-794A4979-034D-497D-905F-FBDDF1FCCE8BQ38941467-AB5F6B53-F55B-4D46-80B9-C631A236454CQ39435385-5C45B8CF-BD7E-4C15-A28F-EA60C16B1960Q40213114-F37E1F3F-0952-452C-BACA-DF9139A6D185Q40217347-E86D95C7-ED67-4B40-B42B-BF95F5365857Q41243702-AEA4A409-F2EF-476A-9817-5090029E7A2AQ41915506-E4E9ACFD-4016-4AC0-8E7E-26D36F7E5D91Q46216597-B14D69D7-BD69-4DAB-902B-1526D56BCE93Q46383671-E2664D65-190B-4F88-A8D0-3152CE1DFA78Q47149669-3E555799-252D-4499-AE3D-DEE922932CB9Q47191569-38D190F6-4D45-4C89-A319-20A099A68088Q47568807-A7A9843F-33B4-4291-A0EC-BA39550DCBD3Q47943881-8F0F984C-AC1E-4910-B600-70579CDE53EAQ47969034-2BE565D5-7171-44E8-94E7-4425A1073C7B
P2860
Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Fixed dosing versus body size- ...... dies in adult clinical trials.
@en
Fixed dosing versus body size- ...... dies in adult clinical trials.
@nl
type
label
Fixed dosing versus body size- ...... dies in adult clinical trials.
@en
Fixed dosing versus body size- ...... dies in adult clinical trials.
@nl
prefLabel
Fixed dosing versus body size- ...... dies in adult clinical trials.
@en
Fixed dosing versus body size- ...... dies in adult clinical trials.
@nl
P2093
P2860
P356
P1476
Fixed dosing versus body size- ...... dies in adult clinical trials.
@en
P2093
Angela Y Men
Diane D Wang
Kourosh Parivar
Shuzhong Zhang
P2860
P304
P356
10.1177/0091270009337512
P577
2009-07-20T00:00:00Z